Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    CVM

Delayed Quote. Delayed  - 09/26 09:59:47 pm
0.435 USD   +2.35%
05:20a CEL SCI : NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck C..
05:04a CEL SCI : Reports Clinical Hold on Head and Neck Cancer Study
09/06 CEL SCI : NEW STORY CEL-SCI Announces Resignation of Its Founder for..
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/27/2016 | 05:20am CEST

CEL-SCI ANNOUNCES RESIGNATION OF ITS FOUNDER FOR HEALTH REASONS

Vienna, VA, September 26, 2016 -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed. CEL-SCI was also told to expect a formal letter from the FDA within 30 days and will work diligently with the FDA to obtain the release of the clinical hold. The study currently has about 926 patients enrolled.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is an improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial at UCSF. CEL-SCI has issued patents on Multikine from the US, Europe, China and Japan.

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words 'intends,' 'believes,' 'anticipated,' 'plans' and 'expects,' and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2015. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

*Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy have not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is currently in progress.

CEL-SCI Corporation published this content on 26 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 September 2016 03:20:05 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CEL-SCI CORPORATION
05:20a CEL SCI : NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
05:04a CEL SCI : Reports Clinical Hold on Head and Neck Cancer Study
09/15 CEL SCI : Reports Monthly Patient Enrollment in August for Its Phase 3 Head and ..
09/15 CEL SCI : Announces Resignation of its Founder for Health Reasons
09/09 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
09/06 CEL SCI : NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reas..
09/06 CEL SCI : Announces Resignation of its Founder for Health Reasons
09/02 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its..
09/02 CEL SCI : Reports Monthly Patient Enrollment in August for Its Phase 3 Head and ..
09/02 CEL SCI CORP : Unregistered Sale of Equity Securities, Change in Directors or Pr..
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/06 CEL-SCI founder steps down for health reasons
08/23 CEL-SCI inks $5M private capital raise; shares off 6% premarket
08/10 Cel-Sci reports FQ3 results
05/18 CEL-SCI inks $5M capital raise via private placement; shares off 4% premarket
05/10 Cel-Sci reports FQ2 results
Advertisement
Chart CEL-SCI CORPORATION
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | CVM | US1508375086 | 4-Traders
Full-screen chart
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION14.86%66
AMGEN, INC.6.90%130 813
GILEAD SCIENCES, INC.-20.33%107 381
CELGENE CORPORATION-11.23%84 821
REGENERON PHARMACEUTIC..-25.56%43 212
VERTEX PHARMACEUTICALS..-29.83%22 456
More Results